Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: Amlodipine and Candesartan Trial in Yokohama (ACTY)

Clinical and Experimental Hypertension

Volumn 34, Issue 4, 2012, Pages 249-257

  Maeda, Akinobu ^a   Tamura, Kouichi ^a   Kanaoka, Tomohiko ^a   Ohsawa, Masato ^a   Haku, Sona ^a   Azushima, Kengo ^a   Dejima, Toru ^a   Wakui, Hiromichi ^a   Yanagi, Mai ^a   Okano, Yasuko ^a   Fujikawa, Tetsuya ^a   Toya, Yoshiyuki ^a   Mizushima, Shunsaku ^a   Tochikubo, Osamu ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

arterial stiffness; central systolic blood pressure; hypertension; insulin resistance; renal function; therapy

Indexed keywords

ALBUMIN; AMLODIPINE; CANDESARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; JAPANESE; MALE; PLEIOTROPY; TREATMENT OUTCOME;

AGED; ALBUMINURIA; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84862217976     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.681081     Document Type: Article

References (44)

1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
2. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033. (Pubitemid 41773378)
3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
4. Ogihara T, Kikuchi K, Matsuoka H, et al. Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
5. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009; 32:962-968.
6. Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 2006; 11:27-32. (Pubitemid 44124125)
7. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30:219-228. (Pubitemid 46605446)
8. Kips JG, Schutte AE, Vermeersch SJ, et al. Comparison of central pressure estimates obtained from SphygmoCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens 2011; 29:1115-1120.
9. Rezai MR, Goudot G, Winters C, Finn JD, Wu FC, Cruickshank JK. Calibration mode influences central blood pressure differences between SphygmoCor and two newer devices, the arteriograph and Omron HEM-9000. Hypertens Res 2011;34:1046-1051.
10. Tomiyama H, Odaira M, Matsumoto C, et al. Effects of moderate-to-severe impairment of the estimated glomerular filtration rate and of proteinuria on the central hemodynamics and arterial stiffness in middle-aged healthy Japanese men. Int J Nephrol 2011; 2011:427471.
11. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25:359-364. (Pubitemid 34752554)
12. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32:950-955.
13. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207:186-190.
14. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51:393-398. (Pubitemid 351159955)
15. Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30:1581-1583. (Pubitemid 46871176)
16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
17. Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009; 32:51-58.
18. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173-1181.
19. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
20. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:572-586.
21. Ichihara A, Kaneshiro Y, Sakoda M, Takemitsu T, Itoh H. Addon amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2007; 49:161-166. (Pubitemid 46579950)
22. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58:155-160.
23. Parati G, Di Rienzo M, Mancia G. Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability. Ann NY Acad Sci 1996; 783:47-63. (Pubitemid 26372080)
24. Tamura K, Tsurumi Y, Sakai M, et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007; 29:31-42.
25. Eto M, Toba K, Akishita M, et al. Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability. Hypertens Res 2003;26:991-998. (Pubitemid 38128772)
26. Kudo H, Kai H, Kajimoto H, et al. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009; 54:832-838.
27. Eguchi K, Ishikawa J, Hoshide S, et al. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009;22:46-51.
28. Ozawa M, Tamura K, Okano Y, et al. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens 2009; 31:669-679.
29. Shigenaga A, Tamura K, Dejima T, et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112:c31-c40.
30. Shintani Y, Kikuya M, Hara A, et al. Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study. J Hypertens 2007;25:1704-1710. (Pubitemid 47056579)
31. Kanaoka T, Tamura K, Moriya T, et al. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy-a pilot study. Clin Exp Hypertens 2011; 33:255-263.
32. Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36:901-906.
33. Eto M, Toba K, Akishita M, et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005; 28:1-7. (Pubitemid 40584956)
34. Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 2008; 52:1045-1050.
35. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906-915.
36. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. LancetNeurol 2010; 9: 469-480.
37. Ushigome E, Fukui M, Hamaguchi M, et al. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res 2011; 34:1271-1275.
38. Manios E, Stamatelopoulos K, Tsivgoulis G, et al. Time rate of blood pressure variation: a new factor associated with coronary atherosclerosis. J Hypertens 2011; 29:1109-1114.
39. Bilo G, Parati G. Rate of blood pressure changes assessed by 24 h ambulatory blood pressure monitoring: another meaningful index of blood pressure variability? J Hypertens 2011; 29:1054-1058.
40. Tamura K, Azushima K, Umemura S. Day-by-day homemeasured blood pressure variability: another important factor in hypertension with diabetic nephropathy? Hypertens Res 2011;34:1249-1250.
41. Iwai M, Li HS, Chen R, et al. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006; 319:1081-1087.
42. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716-723.
43. Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calciumchannel blocker. Am J Hypertens 2011; 24:466-473.
44. Tamura K, Kanaoka T, Ohsawa M, et al. Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. Am J Cardiovasc Dis 2011;1:236-243.